Adaptive Dunnett Tests for Treatment Selection

Size: px
Start display at page:

Download "Adaptive Dunnett Tests for Treatment Selection"

Transcription

1 s for Treatment Selection Franz König 1 Werner Brannath 1 Frank Bretz 2 Martin Posch 1 1 Section of Medical Statistics Medical University of Vienna 2 Novartis Pharma AG Basel Workshop Adaptive Designs 2006 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 1 / 18

2 Motivation Flexible vs Classical frequentist designs Flexible (Adaptive) Versus Frequentist Trial Classical frequentist trials details of design and analysis must be prefixed in advance (population, treatments, doses, main and secondary outcome variable(s), analysis strategy, sample sizes,...) lack of flexibility to react to information from inside or outside the trial Flexible (adaptive) design allow for mid-trial design modifications based on all internal and external information gathered at interim analyses without compromising the type I error rate To control the type I error rate, the design modifications need not be specified in advance. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 2 / 18

3 Seamless Designs Drug Development Flexible Trials and Drug Development Full flexibility (unscheduled adaptivity)= adapting design parameters without a (complete) specification of the adaptation rule. dealing with the unexpected dealing with the expected unpredictability of clinical trials Flexible designs allow to... integrate Phase II and Phase III trials into a single trial (adaptive seamless designs, e.g., Bauer & Kieser 1999, Bretz et al 2006,...) formally integrate the data of exploratory and confirmatory phases speed up the drug development process react flexibly to unexpected events Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 3 / 18

4 Seamless Designs Treatment selection Flexible Trial with Treatment Selection (Phase II + III) Comparison of k treatments with a control. Treatments are selected during the trial. Selection rule need not be laid down in detail in advance. Scientific expert knowledge not known at the planning stage will influence the decision process. Selection rule is complex and unknown at planning stage. Treatment selection may be based on un-blinded interim data on the primary efficacy endpoint, secondary and safety endpoints, external information. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 4 / 18

5 Seamless Designs Treatment selection Flexible Trial with Treatment Selection (Phase II + III) Comparison of k treatments with a control. Treatments are selected during the trial. Selection rule can not? be laid down in detail in advance. Scientific expert knowledge not known at the planning stage will influence the decision process. Selection rule is complex and unknown at planning stage. Treatment selection may be based on un-blinded interim data on the primary efficacy endpoint, secondary and safety endpoints, external information. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 4 / 18

6 Seamless Designs Multiple type I error Treatment Selection & Multiple Testing Identify effective treatments while controlling the multiple type I error rate in the strong sense: Multiple type I error rate: The probability that at least one ineffective treatment is declared effective is controlled regardless of the number of (non-)effective treatments. Multiple testing procedures: Bonferroni, Dunnett... Test Designs with Treatment Selection Group Sequential Tests (Jennison & Turnbull, 2000) Tests with predefined selection rules (Thall et al. 1988, 1989, Stallard & Todd 2003) Combination Tests combined with the closed testing principle (Kieser et al. 1999, Bauer & Kieser 1999, Hommel 2001, Hommel & Kropf 2001,...) Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 5 / 18

7 Seamless Designs Setup The Testing Problem Parallel group design with k = 2 treatments T 1 and T 2 and a control group T 0. Normal responses with common (known) variance (σ = 1). Testing the one sided hypotheses for the means at multiple level α = H 0,1 : µ 1 µ 0 = 0 vs H 1,1 : µ 1 µ 0 > 0 H 0,2 : µ 2 µ 0 = 0 vs H 1,2 : µ 2 µ 0 > 0 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 6 / 18

8 Classical Dunnett Test Treatment selection Treatment Selection with the Classical Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the critical boundaries of the original Dunnet test (correcting for k comparisons) to the remaining treatment control comparisons. Remarks Very Simple Approach No other adaptations (e.g. sample size reassessment) are possible The procedure is strictly conservative Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 7 / 18

9 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 YES NO H 0,1 and H 0,2 are accepted. Test ϕ 1 at level α for Test ϕ 2 at level α for Z H 0,1 H 0,2 1 d1 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18

10 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18

11 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2??? Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18

12 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2 = ) d2!!! Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons Note that d 2 > d 1. This is a strictly conservative test if only one treatment is selected! Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18

13 Procedure Treatment Selection with the Adaptive Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the closure principle with conditional error rates of Dunnett tests for the intersection hypotheses. Remarks The procedure controls the multiple level. Improves the Classical Dunnett test uniformly in the case of treatment selection. Further adaptations are possible Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 9 / 18

14 Procedure Treatment Selection with the Adaptive Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the closure principle with conditional error rates of Dunnett tests for the intersection hypotheses. Remarks The procedure controls the multiple level. Improves the Classical Dunnett test uniformly in the case of treatment selection. Further adaptations are possible Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 9 / 18

15 Conditional Error The Conditional Error Rate Principle Consider a test ϕ to test a hypothesis H 0. The conditional error rate principle (Müller & Schäfer 2001) At an interim analysis we compute: A(interim data) = P H0 ( ϕ rejects H0 interim data ) Continue with an independent second stage and a test for H 0 at level A(interim data). In the final analysis reject H 0 iff q A(interim data), where q is the p-value from the second stage data The resulting procedure controls the level α. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

16 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 Test ϕ 1 at level α H 0,1 Test ϕ 2 at level α H 0,2 After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

17 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 Test ϕ 1 at level α Test ϕ 2 at level α H 0,1 H 0,2 Z1 d1 Z2 d1 After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

18 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 q12 A 12(interim data T 0,T 1 & T 2) Test ϕ 1 at level α Test ϕ 2 at level α H 0,1 H 0, q1 A 1(interim data T 0,T 1) q A (interim data T,T ) After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

19 Closure principle and the conditional error The Adaptive Dunnett Test Selecting only Treatment 1 Dunnett test ϕ 12 at level α for H 0,1 H 0,2 q 1 A 12(interim data T 0,T1 &T 2) Test ϕ 1 at level α H 0,1 q1 A 1(interim data T 0,T 1) Test ϕ 2 at level α H 0,2 q2 A 2(interim data T 0,T 2) After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

20 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

21 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

22 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

23 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

24 Simulation results A Simulation Study Parallel group design with k = 2 treatments with control. Normal responses with common (known) variance (σ = 1). Testing the one sided hypotheses for the means at multiple level α = Remark for simulations Maximum sample size n for each group: such that the single stage test at the unadjusted level has power 80% at standardized treatment effect of alternative µ 1 µ 0 = 0.5 (σ = 1). interim analysis after n 1 = n/2 observations per treatment group simulation runs for each parameter combination Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

25 Simulation results Selecting the treatment with larger effect at interim µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

26 Simulation results Selecting the treatment with larger effect at interim µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

27 Summary adaptive Dunnett test Adaptive Dunnett Test The Conditional error in combination with the closed test principle reduce the conservatism of the Dunnett test with treatment selection If all treatments are selected (and no other adaptations) then the adaptive Dunnett test coincides with the conventinal step down Dunnett test. One can incorporate early rejection and acceptance boundaries at interim analysis. Full flexibility Reassessment or reallocation of sample size, e.g.: reallocate the sample size of a dropped treatment equally to all treatments still under investigation. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

28 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

29 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

30 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

31 Conlusion Conclusion: Adaptive Dunnett Test Take Home Message Start with a Dunnett Test For full flexiblity: conditional error together with the closed test Properties In principle, after every observation adaptations can be performed The interim analysis need not to be preplanned. The adaptation rules need to to be prefixed. The multiple type I error rate is controlled. Back to Reality Nobody in a clinical trial realistically would calculate the conditional error rate after every observation. However, the general principle show that an interim analysis can be performed whenever it seems appropriate without any preplanning. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

32 Conlusion Selected References Koenig, F., Brannath, W., Bretz, F., Bauer, P., and Posch, M. Adaptive Dunnett tests for treatment selection. Working Paper Bretz F, Schmidli H, Koenig F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts. Biometrical Journal 2006; 48(4): Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001; 43: Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57: Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18: Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18

Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim

Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University

More information

Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests.

Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. 1/35 Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. Martin Posch Center for Medical Statistics, Informatics and Intelligent Systems Medical University

More information

Estimation in Flexible Adaptive Designs

Estimation in Flexible Adaptive Designs Estimation in Flexible Adaptive Designs Werner Brannath Section of Medical Statistics Core Unit for Medical Statistics and Informatics Medical University of Vienna BBS and EFSPI Scientific Seminar on Adaptive

More information

Adaptive Treatment Selection with Survival Endpoints

Adaptive Treatment Selection with Survival Endpoints Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,

More information

Adaptive clinical trials with subgroup selection

Adaptive clinical trials with subgroup selection Adaptive clinical trials with subgroup selection Nigel Stallard 1, Tim Friede 2, Nick Parsons 1 1 Warwick Medical School, University of Warwick, Coventry, UK 2 University Medical Center Göttingen, Göttingen,

More information

Group sequential designs for Clinical Trials with multiple treatment arms

Group sequential designs for Clinical Trials with multiple treatment arms Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework

More information

Superchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation

Superchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation August 01, 2012 Disclaimer: This presentation reflects the views of the author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration Introduction We describe

More information

Finding Critical Values with Prefixed Early. Stopping Boundaries and Controlled Type I. Error for A Two-Stage Adaptive Design

Finding Critical Values with Prefixed Early. Stopping Boundaries and Controlled Type I. Error for A Two-Stage Adaptive Design Finding Critical Values with Prefixed Early Stopping Boundaries and Controlled Type I Error for A Two-Stage Adaptive Design Jingjing Chen 1, Sanat K. Sarkar 2, and Frank Bretz 3 September 27, 2009 1 ClinForce-GSK

More information

Adaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013

Adaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Adaptive designs beyond p-value combination methods Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Outline Introduction Combination-p-value method and conditional error function

More information

Adaptive Designs: Why, How and When?

Adaptive Designs: Why, How and When? Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:

More information

Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications

Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications 64 Biometrical Journal 56 24 4, 64 63 DOI:.2/bimj.2353 Maximum type error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications Alexandra C. Graf,2, Peter Bauer,

More information

Testing a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials

Testing a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in

More information

ADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES

ADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES ADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES Christopher Jennison Department of Mathematical Sciences, University of Bath, Bath BA2 7AY, U. K. email: cj@maths.bath.ac.uk and

More information

Comparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design

Comparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj

More information

Adaptive Survival Trials

Adaptive Survival Trials arxiv:1405.1569v1 [stat.ap] 7 May 2014 Adaptive Survival Trials Dominic Magirr 1, Thomas Jaki 2, Franz Koenig 1, and Martin Posch 1 1 Section for Medical Statistics, Medical University of Vienna, Austria

More information

An extrapolation framework to specify requirements for drug development in children

An extrapolation framework to specify requirements for drug development in children An framework to specify requirements for drug development in children Martin Posch joint work with Gerald Hlavin Franz König Christoph Male Peter Bauer Medical University of Vienna Clinical Trials in Small

More information

clinical trials Abstract Multi-arm multi-stage (MAMS) trials can improve the efficiency of the drug

clinical trials Abstract Multi-arm multi-stage (MAMS) trials can improve the efficiency of the drug A multi-stage drop-the-losers design for multi-arm clinical trials James Wason 1, Nigel Stallard 2, Jack Bowden 1, and Christopher Jennison 3 1 MRC Biostatistics Unit, Cambridge 2 Warwick Medical School,

More information

The Design of Group Sequential Clinical Trials that Test Multiple Endpoints

The Design of Group Sequential Clinical Trials that Test Multiple Endpoints The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull

More information

Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection

Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection Research Article Statistics Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection Thomas

More information

Two-Phase, Three-Stage Adaptive Designs in Clinical Trials

Two-Phase, Three-Stage Adaptive Designs in Clinical Trials Japanese Journal of Biometrics Vol. 35, No. 2, 69 93 (2014) Preliminary Report Two-Phase, Three-Stage Adaptive Designs in Clinical Trials Hiroyuki Uesaka 1, Toshihiko Morikawa 2 and Akiko Kada 3 1 The

More information

Confidence intervals and point estimates for adaptive group sequential trials

Confidence intervals and point estimates for adaptive group sequential trials Confidence intervals and point estimates for adaptive group sequential trials Lingyun Liu, Ph.D. Cytel Inc. August 02, 2011 Miami, FL Lingyun Liu (Cytel Inc.) JSM August 02, 2011 Miami, FL 1 / 19 Acknowledgement

More information

The Limb-Leaf Design:

The Limb-Leaf Design: The Limb-Leaf Design: A New Way to Explore the Dose Response Curve in Adaptive Seamless Phase II/III Trials John Spivack Submitted in partial fulfillment of the Requirements for the degree of Doctor of

More information

Repeated confidence intervals for adaptive group sequential trials

Repeated confidence intervals for adaptive group sequential trials STATISTICS IN MEDICINE Statist. Med. 2007; 26:5422 5433 Published online 4 October 2007 in Wiley InterScience (www.interscience.wiley.com).3062 Repeated confidence intervals for adaptive group sequential

More information

Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests

Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests K. Strassburger 1, F. Bretz 2 1 Institute of Biometrics & Epidemiology German Diabetes Center,

More information

MULTISTAGE AND MIXTURE PARALLEL GATEKEEPING PROCEDURES IN CLINICAL TRIALS

MULTISTAGE AND MIXTURE PARALLEL GATEKEEPING PROCEDURES IN CLINICAL TRIALS Journal of Biopharmaceutical Statistics, 21: 726 747, 2011 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543406.2011.551333 MULTISTAGE AND MIXTURE PARALLEL

More information

Adaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, using Locally Efficient Estimators to Improve Precision

Adaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, using Locally Efficient Estimators to Improve Precision Adaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, using Locally Efficient Estimators to Improve Precision MICHAEL ROSENBLUM, TIANCHEN QIAN, YU DU, and HUITONG QIU Department of

More information

Mixtures of multiple testing procedures for gatekeeping applications in clinical trials

Mixtures of multiple testing procedures for gatekeeping applications in clinical trials Research Article Received 29 January 2010, Accepted 26 May 2010 Published online 18 April 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.4008 Mixtures of multiple testing procedures

More information

Pubh 8482: Sequential Analysis

Pubh 8482: Sequential Analysis Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,

More information

On Generalized Fixed Sequence Procedures for Controlling the FWER

On Generalized Fixed Sequence Procedures for Controlling the FWER Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 On Generalized Fixed Sequence Procedures for Controlling the FWER Zhiying Qiu, a Wenge Guo b and Gavin Lynch c Testing

More information

OPTIMAL, TWO STAGE, ADAPTIVE ENRICHMENT DESIGNS FOR RANDOMIZED TRIALS USING SPARSE LINEAR PROGRAMMING

OPTIMAL, TWO STAGE, ADAPTIVE ENRICHMENT DESIGNS FOR RANDOMIZED TRIALS USING SPARSE LINEAR PROGRAMMING Johns Hopkins University, Dept. of Biostatistics Working Papers 6-1-2017 OPTIMAL, TWO STAGE, ADAPTIVE ENRICHMENT DESIGNS FOR RANDOMIZED TRIALS USING SPARSE LINEAR PROGRAMMING Michael Rosenblum Department

More information

Sequential/Adaptive Benchmarking

Sequential/Adaptive Benchmarking Sequential/Adaptive Benchmarking Manuel J. A. Eugster Institut für Statistik Ludwig-Maximiliams-Universität München Validation in Statistics and Machine Learning, 2010 1 / 22 Benchmark experiments Data

More information

Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem

Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong

More information

University of California, Berkeley

University of California, Berkeley University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series Year 2010 Paper 267 Optimizing Randomized Trial Designs to Distinguish which Subpopulations Benefit from

More information

SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS

SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS Journal of Biopharmaceutical Statistics, 18: 1184 1196, 2008 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400802369053 SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE

More information

Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children

Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children Lisa Hampson, Franz Koenig and Martin Posch Department of Mathematics

More information

A Type of Sample Size Planning for Mean Comparison in Clinical Trials

A Type of Sample Size Planning for Mean Comparison in Clinical Trials Journal of Data Science 13(2015), 115-126 A Type of Sample Size Planning for Mean Comparison in Clinical Trials Junfeng Liu 1 and Dipak K. Dey 2 1 GCE Solutions, Inc. 2 Department of Statistics, University

More information

An Alpha-Exhaustive Multiple Testing Procedure

An Alpha-Exhaustive Multiple Testing Procedure Current Research in Biostatistics Original Research Paper An Alpha-Exhaustive Multiple Testing Procedure, Mar Chang, Xuan Deng and John Balser Boston University, Boston MA, USA Veristat, Southborough MA,

More information

A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications

A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications Thomas Brechenmacher (Dainippon Sumitomo Pharma Co., Ltd.) Jane Xu (Sunovion Pharmaceuticals Inc.) Alex Dmitrienko

More information

Blinded sample size reestimation with count data

Blinded sample size reestimation with count data Blinded sample size reestimation with count data Tim Friede 1 and Heinz Schmidli 2 1 Universtiy Medical Center Göttingen, Germany 2 Novartis Pharma AG, Basel, Switzerland BBS Early Spring Conference 2010

More information

The Design of a Survival Study

The Design of a Survival Study The Design of a Survival Study The design of survival studies are usually based on the logrank test, and sometimes assumes the exponential distribution. As in standard designs, the power depends on The

More information

CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity

CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various

More information

Alpha-recycling for the analyses of primary and secondary endpoints of. clinical trials

Alpha-recycling for the analyses of primary and secondary endpoints of. clinical trials Alpharecycling for the analyses of primary and secondary endpoints of Presenters: clinical trials Mohammad Huque, Ph.D. FDA/CDER/OTS/ Office of Biostatistics Sirisha Mushti, Ph.D. Division of Biometrics

More information

A note on tree gatekeeping procedures in clinical trials

A note on tree gatekeeping procedures in clinical trials STATISTICS IN MEDICINE Statist. Med. 2008; 06:1 6 [Version: 2002/09/18 v1.11] A note on tree gatekeeping procedures in clinical trials Alex Dmitrienko 1, Ajit C. Tamhane 2, Lingyun Liu 2, Brian L. Wiens

More information

Are Flexible Designs Sound?

Are Flexible Designs Sound? Biometrics 62, 664 683 September 2006 Are Flexible Designs Sound? Carl-Fredrik Burman and Christian Sonesson AstraZeneca R & D, SE-431 83 Mölndal, Sweden email: carl-fredrik.burman@astrazeneca.com Summary.

More information

BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES

BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES IBRAHIM TURKOZ, PhD Janssen Research & Development LLC, NJ BASS XX Nov, 013 BASS XX 1 Outline Introduction

More information

Sample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018

Sample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018 Sample Size Re-estimation in Clinical Trials: Dealing with those unknowns Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj University of Kyoto,

More information

Original citation: Kimani, Peter K., Todd, Susan and Stallard, Nigel. (03) Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine. ISSN

More information

ROI ANALYSIS OF PHARMAFMRI DATA:

ROI ANALYSIS OF PHARMAFMRI DATA: ROI ANALYSIS OF PHARMAFMRI DATA: AN ADAPTIVE APPROACH FOR GLOBAL TESTING Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Department of Statistics and Warwick Centre of Analytical Sciences,

More information

Optimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping

Optimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping : Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology

More information

Stepwise Gatekeeping Procedures in Clinical Trial Applications

Stepwise Gatekeeping Procedures in Clinical Trial Applications 984 Biometrical Journal 48 (2006) 6, 984 991 DOI: 10.1002/bimj.200610274 Stepwise Gatekeeping Procedures in Clinical Trial Applications Alex Dmitrienko *,1, Ajit C. Tamhane 2, Xin Wang 2, and Xun Chen

More information

Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series

Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Year: 2013 #006 The Expected Value of Information in Prospective Drug Safety Monitoring Jessica M. Franklin a, Amanda R. Patrick

More information

Precision of maximum likelihood estimation in adaptive designs

Precision of maximum likelihood estimation in adaptive designs Research Article Received 12 January 2015, Accepted 24 September 2015 Published online 12 October 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.6761 Precision of maximum likelihood

More information

Group-Sequential Tests for One Proportion in a Fleming Design

Group-Sequential Tests for One Proportion in a Fleming Design Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming

More information

Exact Inference for Adaptive Group Sequential Designs

Exact Inference for Adaptive Group Sequential Designs STATSTCS N MEDCNE Statist. Med. 2013; 00:1 [Version: 2002/09/18 v1.11] Exact nference for Adaptive Group Sequential Designs Ping Gao 1, Lingyun Liu 2, Cyrus R. Mehta 2,3 1 The Medicines Company, 2 Cytel

More information

Group Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology

Group Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,

More information

Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation

Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.100/sim.0000 Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample

More information

Group Sequential Designs: Theory, Computation and Optimisation

Group Sequential Designs: Theory, Computation and Optimisation Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference

More information

Optimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives

Optimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives Optimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives Thomas Ondra Sebastian Jobjörnsson Section for Medical Statistics, Medical

More information

Bayesian concept for combined Phase 2a/b trials

Bayesian concept for combined Phase 2a/b trials Bayesian concept for combined Phase 2a/b trials /////////// Stefan Klein 07/12/2018 Agenda Phase 2a: PoC studies Phase 2b: dose finding studies Simulation Results / Discussion 2 /// Bayer /// Bayesian

More information

ROI analysis of pharmafmri data: an adaptive approach for global testing

ROI analysis of pharmafmri data: an adaptive approach for global testing ROI analysis of pharmafmri data: an adaptive approach for global testing Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Abstract Pharmacological fmri (pharmafmri) is a new highly

More information

Testing a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial

Testing a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial Testing a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial ExL Pharma Workshop 2010 Rockville, MD Cyrus R. Mehta President, Cytel Corporation January 26, 2010 email: mehta@cytel.com

More information

arxiv: v2 [stat.me] 24 Aug 2018

arxiv: v2 [stat.me] 24 Aug 2018 Conditional Estimation in Two-stage Adaptive Designs Per Broberg Division of Cancer Epidemiology, Department of Clinical Sciences Lund, Lund University, Skane University Hospital, Lund, Sweden. Email:

More information

A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks

A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks A Gatekeeping Test in a Group Sequential Design 1 A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks Ajit C. Tamhane Department of Industrial

More information

AN INVESTIGATION OF TWO-STAGE TESTS. Marc Vandemeulebroecke. Otto-von-Guericke-Universität Magdeburg. and. Schering AG

AN INVESTIGATION OF TWO-STAGE TESTS. Marc Vandemeulebroecke. Otto-von-Guericke-Universität Magdeburg. and. Schering AG AN INVESTIGATION OF TWO-STAGE TESTS Marc Vandemeulebroecke Otto-von-Guericke-Universität Magdeburg and Schering AG Abstract: Two-stage tests may be defined in terms of a combination function for the p-values

More information

Pubh 8482: Sequential Analysis

Pubh 8482: Sequential Analysis Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 12 Review So far... We have discussed the role of phase III clinical trials in drug development

More information

Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping

Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj

More information

Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs. Christopher Jennison

Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs. Christopher Jennison Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs Christopher Jennison Department of Mathematical Sciences, University of Bath http://people.bath.ac.uk/mascj

More information

Bayesian methods for sample size determination and their use in clinical trials

Bayesian methods for sample size determination and their use in clinical trials Bayesian methods for sample size determination and their use in clinical trials Stefania Gubbiotti Abstract This paper deals with determination of a sample size that guarantees the success of a trial.

More information

Group Sequential Tests for Delayed Responses

Group Sequential Tests for Delayed Responses Group Sequential Tests for Delayed Responses Lisa Hampson Department of Mathematics and Statistics, Lancaster University, UK Chris Jennison Department of Mathematical Sciences, University of Bath, UK Read

More information

Some Notes on Blinded Sample Size Re-Estimation

Some Notes on Blinded Sample Size Re-Estimation Some Notes on Blinded Sample Size Re-Estimation arxiv:1301.4167v1 [stat.me] 17 Jan 013 Ekkehard Glimm 1 and Jürgen Läuter Abstract This note investigates a number of scenarios in which unadjusted testing

More information

Optimal exact tests for multiple binary endpoints

Optimal exact tests for multiple binary endpoints Optimal exact tests for multiple binary endpoints Robin Ristl 1, Dong Xi, Ekkehard Glimm 3,4, Martin Posch 1 December 3, 16 arxiv:161.7561v1 [stat.me] Dec 16 Abstract In confirmatory clinical trials with

More information

Multiple Testing in Group Sequential Clinical Trials

Multiple Testing in Group Sequential Clinical Trials Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics

More information

UNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION

UNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION UNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION BY MICHAEL ROSENBLUM Department of Biostatistics, Johns Hopkins Bloomberg

More information

Two-stage Adaptive Randomization for Delayed Response in Clinical Trials

Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Guosheng Yin Department of Statistics and Actuarial Science The University of Hong Kong Joint work with J. Xu PSI and RSS Journal

More information

Contrasts (in general)

Contrasts (in general) 10/1/015 6-09/749 Experimental Design for Behavioral and Social Sciences Contrasts (in general) Context: An ANOVA rejects the overall null hypothesis that all k means of some factor are not equal, i.e.,

More information

An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary

An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary Ying Zhang and William R. Clarke Department of Biostatistics, University of Iowa 200 Hawkins Dr. C-22 GH, Iowa City,

More information

Group Sequential Trial with a Biomarker Subpopulation

Group Sequential Trial with a Biomarker Subpopulation Group Sequential Trial with a Biomarker Subpopulation Ting-Yu (Jeff) Chen, Jing Zhao, Linda Sun and Keaven Anderson ASA Biopharm Workshop, Sep 13th. 2018 1 Outline Motivation: Phase III PD-L1/PD-1 Monotherapy

More information

Bonferroni - based gatekeeping procedure with retesting option

Bonferroni - based gatekeeping procedure with retesting option Bonferroni - based gatekeeping procedure with retesting option Zhiying Qiu Biostatistics and Programming, Sanofi Bridgewater, NJ 08807, U.S.A. Wenge Guo Department of Mathematical Sciences New Jersey Institute

More information

Two-Stage Sequential Designs Regulatory Perspective

Two-Stage Sequential Designs Regulatory Perspective Wikimedia Commons 2007 Sokoljan Creative Commons SA 3.0 Unported Two-Stage Sequential Designs Regulatory Perspective Helmut Schütz BA/BE Workshop Prague, 22 September 2016 1 Disclaimer I am not a regulator.

More information

On the efficiency of two-stage adaptive designs

On the efficiency of two-stage adaptive designs On the efficiency of two-stage adaptive designs Björn Bornkamp (Novartis Pharma AG) Based on: Dette, H., Bornkamp, B. and Bretz F. (2010): On the efficiency of adaptive designs www.statistik.tu-dortmund.de/sfb823-dp2010.html

More information

Reports of the Institute of Biostatistics

Reports of the Institute of Biostatistics Reports of the Institute of Biostatistics No 01 / 2010 Leibniz University of Hannover Natural Sciences Faculty Titel: Multiple contrast tests for multiple endpoints Author: Mario Hasler 1 1 Lehrfach Variationsstatistik,

More information

Citation for final published version: Publishers page:

Citation for final published version: Publishers page: This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/110115/ This is the author s version of a work that was submitted to / accepted

More information

Controlling the False Discovery Rate in Two-Stage. Combination Tests for Multiple Endpoints

Controlling the False Discovery Rate in Two-Stage. Combination Tests for Multiple Endpoints Controlling the False Discovery Rate in Two-Stage Combination Tests for Multiple ndpoints Sanat K. Sarkar, Jingjing Chen and Wenge Guo May 29, 2011 Sanat K. Sarkar is Professor and Senior Research Fellow,

More information

2015 Duke-Industry Statistics Symposium. Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data

2015 Duke-Industry Statistics Symposium. Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data 2015 Duke-Industry Statistics Symposium Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data Victoria Chang Senior Statistician Biometrics and Data Management

More information

Inverse Sampling for McNemar s Test

Inverse Sampling for McNemar s Test International Journal of Statistics and Probability; Vol. 6, No. 1; January 27 ISSN 1927-7032 E-ISSN 1927-7040 Published by Canadian Center of Science and Education Inverse Sampling for McNemar s Test

More information

Overrunning in Clinical Trials: a Methodological Review

Overrunning in Clinical Trials: a Methodological Review Overrunning in Clinical Trials: a Methodological Review Dario Gregori Unit of Biostatistics, Epidemiology and Public Health Department of Cardiac, Thoracic and Vascular Sciences dario.gregori@unipd.it

More information

Familywise Error Rate Controlling Procedures for Discrete Data

Familywise Error Rate Controlling Procedures for Discrete Data Familywise Error Rate Controlling Procedures for Discrete Data arxiv:1711.08147v1 [stat.me] 22 Nov 2017 Yalin Zhu Center for Mathematical Sciences, Merck & Co., Inc., West Point, PA, U.S.A. Wenge Guo Department

More information

Sample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA

Sample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power I: Binary Outcomes James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power Principles: Sample size calculations are an essential part of study design Consider

More information

Monitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs. Christopher Jennison

Monitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs. Christopher Jennison Monitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs Christopher Jennison Department of Mathematical Sciences, University of Bath,

More information

The International Journal of Biostatistics

The International Journal of Biostatistics The International Journal of Biostatistics Volume 7, Issue 1 2011 Article 12 Consonance and the Closure Method in Multiple Testing Joseph P. Romano, Stanford University Azeem Shaikh, University of Chicago

More information

arxiv: v1 [stat.me] 24 Jul 2013

arxiv: v1 [stat.me] 24 Jul 2013 arxiv:1307.6275v1 [stat.me] 24 Jul 2013 A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy Daniel Zelterman Department of Biostatistics School of Epidemiology

More information

Approaches to sample size calculation for clinical trials in small populations

Approaches to sample size calculation for clinical trials in small populations Approaches to sample size calculation for clinical trials in small populations Frank Miller, Statistiska institutionen, Stockholms universitet Stockholm, 24 februari 2016 Joint work This talk is based

More information

Practical issues related to the use of biomarkers in a seamless Phase II/III design

Practical issues related to the use of biomarkers in a seamless Phase II/III design Practical issues related to the use of biomarkers in a seamless Phase II/III design Tomasz Burzykowski International Drug Development Institute Louvain-la-Neuve, Belgium tomasz.burzykowski@iddi.be www.iddi.com

More information

Reports of the Institute of Biostatistics

Reports of the Institute of Biostatistics Reports of the Institute of Biostatistics No 02 / 2008 Leibniz University of Hannover Natural Sciences Faculty Title: Properties of confidence intervals for the comparison of small binomial proportions

More information

Group sequential designs for negative binomial outcomes

Group sequential designs for negative binomial outcomes Group sequential designs for negative binomial outcomes Tobias Mütze a, Ekkehard Glimm b,c, Heinz Schmidli b, and Tim Friede a,d a Department of Medical Statistics, University Medical Center Göttingen,

More information

Simultaneous Confidence Intervals and Multiple Contrast Tests

Simultaneous Confidence Intervals and Multiple Contrast Tests Simultaneous Confidence Intervals and Multiple Contrast Tests Edgar Brunner Abteilung Medizinische Statistik Universität Göttingen 1 Contents Parametric Methods Motivating Example SCI Method Analysis of

More information

Testing hypotheses in order

Testing hypotheses in order Biometrika (2008), 95, 1,pp. 248 252 C 2008 Biometrika Trust Printed in Great Britain doi: 10.1093/biomet/asm085 Advance Access publication 24 January 2008 Testing hypotheses in order BY PAUL R. ROSENBAUM

More information

Group sequential designs with negative binomial data

Group sequential designs with negative binomial data Group sequential designs with negative binomial data Ekkehard Glimm 1 Tobias Mütze 2,3 1 Statistical Methodology, Novartis, Basel, Switzerland 2 Department of Medical Statistics, University Medical Center

More information

Impact of covariate misclassification on the power and type I error in clinical trials using covariate-adaptive randomization

Impact of covariate misclassification on the power and type I error in clinical trials using covariate-adaptive randomization Impact of covariate misclassification on the power and type I error in clinical trials using covariate-adaptive randomization L I Q I O N G F A N S H A R O N D. Y E A T T S W E N L E Z H A O M E D I C

More information

Optimal group sequential designs for simultaneous testing of superiority and non-inferiority

Optimal group sequential designs for simultaneous testing of superiority and non-inferiority Optimal group sequential designs for simultaneous testing of superiority and non-inferiority Fredrik Öhrn AstraZeneca R & D Mölndal, SE-431 83 Mölndal, Sweden and Christopher Jennison Department of Mathematical

More information